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The essential actin-binding factor profilin-1 (Pfn1) is a non-classical tumor suppressor
with the abilities toboth inhibit cellular proliferation and augment chemotherapy-induced
apoptosis. Besides actin, Pfn1 interacts with proteins harboring the poly-L-proline (PLP)
motifs. Our recent work demonstrated that both nuclear localization and PLP-binding
are required for tumor growth inhibition by Pfn1, and this is at least partially due to
Pfn1 association with the PLP-containing ENL protein in the Super Elongation Complex
(SEC) and the transcriptional inhibition of pro-cancer genes. In this paper, by identifying a
phosphorylation event of Pfn1 at Ser71 capable of inhibiting its actin-binding and nuclear
export, we provide in vitro and in vivo evidence that chemotherapy-induced apoptotic
sensitization by Pfn1 requires its cytoplasmic localization and actin-binding. With
regard to tumor growth inhibition byPfn1, our data indicate a requirement for dynamic
actin association and dissociation rendered by reversible Ser71phosphorylation and
dephosphorylation. Furthermore, genetic and pharmacological experiments showed
that Ser71 of Pfn1 can be phosphorylated by protein kinase A (PKA). Taken together,
our data provide novel mechanistic insights into the multifaceted anticancer activities
of Pfn1 and how they are spatially-defined in the cell and differentially regulated by
ligand-binding.
Keywords: profilin-1, phosphorylation, actin, poly-L-proline, apoptosis, breast cancer, chemotherapy, protein
kinase A
INTRODUCTION
As the first actin-binding protein identified more than four decades ago (Carlsson et al., 1977),
profilin-1 (Pfn1) has been extensively studied in the context of actin regulation. By binding
monomeric G-actin, Pfn1 exchanges ADP for ATP and facilitates the addition of ATP-bound
G-actin to the barbed ends of filamentous actin (Haarer and Brown, 1990; Witke, 2004; Jockusch
et al., 2007; Birbach, 2008). In addition, Pfn1 interacts with a wide range of poly-L-proline (PLP)-
containing proteins many of which are actin-regulatory factors and cooperate with Pfn1 to control
actin polymerization (Haarer and Brown, 1990; Witke, 2004; Jockusch et al., 2007; Birbach, 2008).
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Pfn1 is essential for the development and survival of multiple
eukaryotic organisms including mice, Drosophila and yeast
(Balasubramanian et al., 1994; Verheyen and Cooley, 1994; Witke
et al., 2001; Bottcher et al., 2009). Paradoxically, Pfn1 also shows
anti-tumor and anti-metastatic activities for various types of
cancer (breast, pancreatic, and liver) (Janke et al., 2000; Roy and
Jacobson, 2004; Wittenmayer et al., 2004; Ding et al., 2006; Wu
et al., 2006; Zou et al., 2007, 2009, 2010; Bae et al., 2009, 2010;
Das et al., 2009; Yao et al., 2014; Diamond et al., 2015). Our
prior study suggested that some of these anticancer activities
may stem from nuclear Pfn1 (Diamond et al., 2015). Our
more recent work supported this theory and demonstrated that
nuclear Pfn1 functions as a transcriptional repressor by binding
and inhibiting the Super Elongation Complex (SEC), a positive
regulator of transcriptional elongation of many pro-cancer genes
(Zhu et al., 2021). Furthermore, we provided evidence that
Pfn1 undergoes spatial deregulation in a broad range of cancer
due to overexpression of its nuclear exporter exportin-6. This
explains, to some extent, how anticancer activity of nuclear Pfn1
can be inhibited while its essential cytoplasmic functions are
sustained. However, given that Pfn1 influences distinct cancer
phenotypes including proliferation, metastasis, and survival upon
chemotherapy treatments (Zou et al., 2010; Yao et al., 2013; Zaidi
et al., 2016), it remains unclear whether these activities stem from
the same or different subcellular locations and whether there are
additional regulatory mechanisms besides exportin-6-dependent
nuclear export.
We have found in prior and recent studies that PLP-binding is
important for the tumor-inhibitory function of Pfn1 (Diamond
et al., 2015), at least partially due to the direct interaction of
nuclear Pfn1 with ENL, a PLP-containing protein, in the SEC
complex (Zhu et al., 2021). We and others found that PLP-
binding of Pfn1 can be abolished by Ser137 phosphorylation in its
C-terminus (Shao et al., 2008b; Diamond et al., 2015). In addition
to PLP-binding, actin-binding was also suggested to be important
for tumor inhibition by Pfn1. This was based on the loss-of-
function effect of Y59A, an actin-binding mutation of Pfn1
(Schluter et al., 1998; Wittenmayer et al., 2004). However, despite
being the first actin-binding protein identified several decades
ago, it remains unknown whether phosphorylation events exist
in Pfn1 which can inhibit its actin-binding and modulate its
anticancer activities.
In this paper, we identified a protein kinase A (PKA)-
dependent phosphorylation site in Pfn1 at Ser71. Residing in
the actin-binding site of Pfn1, Ser71 phosphorylation abolishes
the Pfn1/actin interaction and causes nuclear retention of Pfn1.
Functional characterization using breast cancer cell lines revealed
that Ser71 phosphorylation regulates both cell proliferation
and chemotherapy-induced apoptosis but in different fashions.
Dissection of the functional influences of subcellular localization
further indicated that while tumor inhibition by Pfn1 is driven
largely by its nuclear activities, apoptosis-sensitizing effect
depends on its cytoplasmic localization. Thus, by identifying and
characterizing a previously unknown inhibitory phosphorylation
event for actin-binding of Pfn1, we provided further mechanistic
insights into its multifaceted tumor-inhibitory activities which
are regulated both by ligand-binding and subcellular localization.
MATERIALS AND METHODS
DNA Constructs
Untagged, Myc-tagged, and HA-tagged Pfn1 in pcDNA3, His-
tagged Pfn1 in pRK172, untagged Pfn1 in pLenti-CMV/TO-
Neo-DEST, and YFP-Pfn1 with and without NES or NLS tag
in pFLRu-FH vector have been described previously (Shao
et al., 2008b; Diamond et al., 2015; Zhu et al., 2021). Point
mutations (S71A and S71D) within Pfn1 were introduced by
site-directed mutagenesis using QuikChange. GFP-tagged PKA
catalytic subunit in EGFP-C1 was purchased from Addgene
(plasmid # 61091).
Antibodies
Primary antibodies used for Western blots are as follows:
mouse anti-HA-tag (Convance, MMS-101P through BioLegend,
United States), mouse anti-Myc-tag (Santa Cruz, United States,
sc-40), mouse anti-β-actin (Santa Cruz, United States, sc-
47778; Cell Signaling, United States, #3700), mouse anti-
α-tubulin (Cell Signaling, United States, #3873), mouse GAPDH
(Santa Cruz, United States, sc-47724), rabbit anti-Pfn1 (Cell
Signaling, United States, #3246), rabbit anti-VASP (Bethyl
laboratories, United States, A304-769A), rabbit anti-cleaved
caspase-7 (Cell Signaling, United States, #8438), rabbit anti-
cleaved PARP (Cell signaling, United States, #9541), rabbit
anti-GFP (Cell Signaling, United States, #2956). To raise the
polyclonal pSer71-Pfn1 antibody (F5675), a synthetic phospho-
Pfn1 peptide harboring pSer71 [Ac-CLGGQKC(pS)VIRDSL-
amide] was conjugated to keyhole limpet hemocyanin and used
to immunize rabbits. Antiserum was subjected to double affinity
purification using both the antigenic phospho-peptide and the
same peptide without the phosphate on Ser71 (New England
Peptide, Inc., United States).
Cell Culture
All cell lines were purchased from ATCC with the exception
of MDA-MB-231 cells stably expressing a tri-modal reporter
fusion used to inject NOD/SCID mice as previously described
(Diamond et al., 2015). All cell lines were authenticated and
tested for mycoplasma within 3 months prior to the experiments.
MDA-MB-231, MCF-7, and BT-549 were grown in RPM1 1,640
containing 5 or 10% fetal bovine serum (FBS) with gentamicin
and supplements (50 µg/mL gentamycin, 1mM sodium pyruvate,
10 mM HEPES and glucose to 4.5 g/L). HEK293T cells were
grown in high glucose DMEM supplemented with 5 or 10% fetal
bovine serum and 50 µg/mL gentamicin. Transient transfection
was performed using Fugene HD or Lipofectamine 2000.
Lentiviruses were generated using HEK293T cells as previously
described (Diamond et al., 2015).
Pull-Down Assays
To study Pfn1 interaction with actin and VASP, HEK293T cells
grown in 6-well dishes were transfected with Myc-tagged or HA-
tagged Pfn1 constructs (WT and mutants), lysed by RIPA buffer,
and subjected to immunoprecipitation using antibodies against
Myc or HA tags as described previously (Shao et al., 2008b;
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Diamond et al., 2015). To affinity purify endogenous Pfn1,
parental MDA-MB-231 cells were lysed and bound to PLP-
conjugated agarose beads as described previously (Shao et al.,
2008b; Diamond et al., 2015).
In Vitro Drug Treatment
For drug treatment in 2D cultures, MDA-MB-231 or BT-549
stable cells were seeded at 1,000 cells per well in 96-well plates
or 500 cells per well in 24-well plates, and treated on the next
day with vehicle or paclitaxel in quadruplicate wells. Viable
cells were quantified 5–7 days later by the Alamar Blue assay
(Diamond et al., 2015; Zhu et al., 2021). Briefly, they were
incubated with 100ul (for 96-well) or 500ul (for 24-well) growth
media containing 44 µM resazurin for 2–4 h at 37◦C, and the
fluorescence intensity of resorufin (converted product) in the
media was measured at 540λ Ex/590λ Em on a fluorescence
plate reader (Tecan Infinite M200). Relative drug effects were
calculated as the percentage of live cells in drug vs. vehicle wells.
Mouse Xenografts
The animal experiment was carried out in strict accordance
with the guidelines recommended for care and use of laboratory
animals by the National Institutes of Health. The Animal
Studies Committee at Washington University (St. Louis, MO,
United States) approved all animal protocols. Five-week old
female NOD/SCID and NU/NU mice were purchased from
Charles River and kept under standard institutional care.
Experimental details for orthotopically inoculating MDA-MB-
231 stable cells were previously described (Diamond et al.,
2015; Zhu et al., 2021). For paclitaxel dosing, when tumors in
the NU/NU mice reached an average of ∼70 mm3, they were
randomly divided and treated with 0.9% sodium chloride or
paclitaxel (10 mg/kg) by weekly intraperitoneal injection for
two consecutive weeks. Clinical grade paclitaxel (6 mg/ml) was
purchased from Siteman Cancer Center pharmacy at Washington
University School of Medicine. Primary tumors were measured
by Caliper on a weekly (for NOD/SCID) and semiweekly
(NU/NU) basis until tumor resection and euthanasia of the mice.
Statistical Analysis
Unpaired two-tailed student t-test was used to determine the
statistical significance of the differences in cell growth rates,
tumor sizes and weights between control and experimental
groups. All statistical analyses were performed using GraphPad




Hypothesizing that actin-binding of Pfn1 can be inhibited by
phosphorylation, we selected five candidate serine/threonine
residues at the actin-binding region of Pfn1 guided by the
actin/Pfn1 co-crystal structure (Figure 1A; Ferron et al., 2007).
Each residue was mutated to alanine (S/A) or aspartate (S/D)
to prevent or mimic phosphorylation. The resulting Myc-
tagged Pfn1 mutants were transfected into HEK293T cells and
immunoprecipitated using an anti-Myc antibody followed by
Western blot to determine their actin-binding. All mutants
were successfully expressed except T89D which was likely due
to a destabilizing effect on Pfn1 structure and its consequent
degradation. Out of the five candidate residues, Ser71 appears
to be a bona fide phosphorylation site as preventing (S71A)
and mimicking (S71D) phosphorylation had opposite effects on
actin-binding of Pfn1. While Pfn1(S71A) binds more actin than
Pfn1(WT), Pfn1(S71D) completely fails to bind actin (Figure 1B).
Introducing the S71A and S71D mutations into an HA-tagged
Pfn1 showed the same effects on actin-binding as for Myc-Pfn1,
but neither mutation had detectable effect on Pfn1 interaction
with vasodilator-stimulated phosphoprotein (VASP), a well-
known PLP-containing ligand of Pfn1 (Reinhard et al., 1995;
Kang et al., 1997; Ferron et al., 2007; Figure 1C).
A search at PhosphoSitePlus revealed that Ser71
phosphorylation of Pfn1 has been detected in several unbiased
mass spectrometry datasets (Klammer et al., 2012; Mertins et al.,
2013, 2016). To confirm this, we developed a polyclonal antibody
FIGURE 1 | Mimicking Ser71 phosphorylation by the S71D mutation abolishes actin-binding of Pfn1. (A) X-ray diffraction structure of human Pfn1 (right, cyan) bound
with actin (left, purple) (Protein Data Bank ID 2PAV) (Ferron et al., 2007). Ser71 and four other serine and threonine residues in the actin-binding region of Pfn1 are
displayed in the sticks mode. (B) HEK293T cells were transfected with Myc-tagged wild type or mutant Pfn1 containing alanine (A) or aspartate (D) substitutions on
the five candidate serine or threonine residues. Lysates were subjected to immunoprecipitation using a Myc-tag antibody, and Western blot was used to detect
Myc-Pfn1 and co-precipitated actin. (C) HEK293T cells were transfected with wild type or mutant forms of HA-tagged Pfn1 containing S71A or S71D, which were
subsequently immunoprecipitated by an anti-HA tag antibody. Lysates were subjected to immunoprecipitation, and samples were blotted for actin, VASP, and
HA-tag (to visualize HA-Pfn1).
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 June 2021 | Volume 9 | Article 692269
fcell-09-692269 June 15, 2021 Time: 17:44 # 4
Wang et al. Ser71 Phosphorylation of Pfn1
FIGURE 2 | Pfn1 is phosphorylated at Ser71 in cultured cells. (A) Equal
amounts of recombinant 6His-Pfn1 (WT, S71A, or S71) purified from bacteria
was stained by Coomassie blue or analyzed by Western blot using the
pSer71-Pfn1 antibody F5675. (B) HA-tagged Pfn1 (WT, S71A, or S71D) was
transfected into HEK293 cells and immunoprecipitated using an anti-HA
antibody. Samples were analyzed by Western blot using the pSer71-Pfn1
antibody (F5675) or the anti-HA antibody. Densitometry was used to quantify
the intensity of bands detected by F5675 and expressed as relative values to
HA-Pfn1(WT). (C) Endogenous Pfn1 was purified from MDA-MB-231 cell
lysates using poly-L-proline (PLP)-conjugated agarose beads, and subjected
to Western blot analysis using the pSer71-Pfn1 antibody (F5675) or a pan
anti-Pfn1 antibody. Input was also blotted with the pSer71-Pfn1 antibody
(F5675) for comparison.
named F5675 using an antigenic Pfn1 peptide harboring
pSer71. Using recombinant 6His-Pfn1 purified from bacteria
(where serines/threonines are largely unphosphorylated), we
observed by Western blot little detection of Pfn1(WT) and
the phospho-resistant Pfn1(S71A) but robust detection of the
phosphomimetic Pfn1(S71D) by F5675 (Figure 2A). Though
chemically different from phospho-serines, phosphomimetic
amino acids such as aspartate (D) or glutamate (E) have been
reported by us and others to react with phospho-antibodies raised
against different proteins (Shao et al., 2008b; Shu et al., 2008).
This thus supports the phospho-specificity of the pSer71-Pfn1
antibody. Consistent with this, HA-Pfn1 immunoprecipitated
from HEK293T cells was positively detected by the pSer71-Pfn1
antibody, and the signal was significantly reduced by the S71A
mutation while enhanced by S71D (Figure 2B). However, we
could not readily detect endogenous Pfn1 within whole cell
lysates using the pSer71-Pfn1 antibody because it recognizes
many other proteins due to its non-specific, polyclonal nature
(Figure 2C, input, second lane). To overcome this, we used
PLP-conjugated agarose beads to purify and enrich endogenous
Pfn1 from the triple-negative breast cancer MDA-MB-231 cell
line. This resulted in clear detection of endogenous Pfn1 by the
pSer71-Pfn1 antibody (Figure 2C, first lane), as confirmed by
the side-by-side blotting with a pan Pfn1 antibody (third lane).
Thus, our data suggest that Pfn1 is phosphorylated on Ser71 in
mammalian cells.
Ser71 Is Phosphorylated by Protein
Kinase A
By comparing Pfn1 and Pfn2 (a functionally related isoform)
(Haarer and Brown, 1990; Witke, 2004; Jockusch et al., 2007;
Birbach, 2008) sequences from various species, we find that Ser71
is evolutionarily conserved in vertebrates (a chemically similar
threonine is present in zebrafish Pfn1) (Figure 3A). Ser71 is
invariably preceded at −2 position by a basic residue (most
commonly Arg), suggesting that it could be phosphorylated by
the AGC kinase family (Pearce et al., 2010). A closer examination
of the sequence surrounding Ser71 and comparing it with the
phosphorylation consensus sites of common AGC kinases at
Human Protein Kinase Knowledgebase revealed that cAMP-
dependent protein kinase [also known as protein kinase A (PKA)]
is a possibility. The preferred amino acids at+1 and+2 positions
for PKA substrates are hydrophobic (F, I, L, and V) while those
for +5 and +6 positions are leucine. The Ser71-containing motif
in Pfn1 meets all these requirements in particular a perfect match
at+5/+6 positions. To test whether PKA is indeed the kinase for
Ser71, we co-transfected HEK293T cells with GFP or GFP-tagged
alpha catalytic subunit of PKA with HA-Pfn1, and examined
the level of Ser71 phosphorylation by Western blot after anti-
HA immunoprecipitation. While equal amount of HA-Pfn1 was
pulled down, co-transfection with GPKA significantly increased
its pSer71 level detected by the F5675 antibody (Figure 3B).
We next treated HEK293T cells co-transfected with HA-Pfn1
and GPKA with DMSO or PKA-specific inhibitor H89, and
performed the same anti-HA immunoprecipitation and Western
blot analyses. H89 significantly decreased pSer71-Pfn1 level
without affecting the total level of HA-Pfn1 (Figure 3C). To
confirm that Ser71, as opposed to other PKA phosphorylation
sites in Pfn1, is detected by the F5675 antibody, we performed
the same co-transfection experiment using either wild type
or S71A mutant form of HA-Pfn1 with GFP or GPKA. We
observed no GPKA-induced increase in the detection of HA-
Pfn1(S71A) by the pSer71-Pfn1 antibody in contrast to HA-
Pfn1(WT) (Figure 3D). As a separate control, mutating Ser137 to
alanine (S137A) did not affect the ability of GPKA to increase the
detection of HA-Pfn1 by the F5675 antibody (Figure 3E). Taken
together, our data suggest that Ser71 is the site of PKA-dependent
phosphorylation of Pfn1.
Antitumor Activity of Pfn1 Requires
Reversible Ser71 Phosphorylation and
Dephosphorylation
Pfn1 overexpression inhibits the growth of various cancer cell
lines in vitro and in vivo (Janke et al., 2000; Wittenmayer
et al., 2004; Wu et al., 2006; Zou et al., 2007, 2010; Das et al.,
2009; Yao et al., 2014). We have previously demonstrated that
the antitumor effect of Pfn1 requires its PLP-binding ability
which is inhibited by Ser137 phosphorylation (Diamond et al.,
2015). To determine the effect of Ser71 phosphorylation, we
virally expressed untagged wild type Pfn1 and its S71A or S71D
mutants in the MDA-MB-231 breast cancer cells at levels 2–3-
folds over endogenous Pfn1 (Figure 4A). GUS, a reporter gene
encoding bacterial β-glucuronidase, was expressed as the negative
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FIGURE 3 | Pfn1 is phosphorylated at Ser71 by protein kinase A (PKA). (A) sequence alignment of Pfn1 and Pfn2 proteins from multiple vertebrate organisms shows
that a phosphorylatable serine or threonine residue is highly conserved at position 71. (B) HEK293T cells were co-transfected with HA-tagged Pfn1 with GFP or
GFP-PKA, followed by anti-HA immunoprecipitation. Pulldown samples were blotted using the pSer71-Pfn1 or pan Pfn1 antibodies. (C) HEK293T cells were
transfected with HA-Pfn1 followed by the treatment with DMSO or 10 µM H89 for 24 h. HA-Pfn1 was subsequently immunoprecipitated and blotted as in (B).
(D) HEK293T cells were co-transfected with HA-Pfn1(WT) or HA-Pfn1(S71A) with GFP or GFP-PKA, followed by immunoprecipitation and Western blot analysis as in
(B, C). (E) HEK293T cells were co-transfected with wild type or mutant HA-Pfn1 (S71A or S137A) with GFP or GFP-PKA, followed by immunoprecipitation and
Western blot analysis as in (B–D).
control as previously described (Diamond et al., 2015). We
first compared the cell proliferation rates in vitro by Alamar
blue assay. While Pfn1(WT) showed anti-proliferative effect as
observed previously, both Pfn1(S71A) and Pfn1(S71D) mutants
were inactive (Figure 4B). We next determined the in vivo
effects by injecting the same stable cells orthotopically in the
mammary fat pads of female NOD/SCID mice as previously
described (Diamond et al., 2015). Caliper measurements showed
that both S71A and S71D mutations abolish the antitumor effect
of Pfn1 and caused an additional increase in tumor growth
compared to the GUS control (Figure 4C). End-point tumor
weights confirmed these effects (Figure 4D). Thus, unlike the
toggling effect of Ser137 phosphorylation, tumor inhibition by
Pfn1 appears to require reversible Ser71 phosphorylation and
dephosphorylation.
Ser71 Phosphorylation Inhibits the
Apoptosis-Sensitizing Activity of Pfn1 in
Response to Paclitaxel
In addition to suppressing proliferation, Pfn1 also sensitizes
cancer cells to apoptosis induced by cytotoxic agents (Zou et al.,
2010; Yao et al., 2013; Zaidi et al., 2016). When transfecting
MDA-MB-231 cells using lipofectamine (which is cytotoxic),
we consistently observed higher number of surviving cells
expressing Pfn1(S71D) than those expressing Pfn1(WT) and
Pfn1(S71A) (Supplementary Figure 1A). A similar effect was
also observed in the transfected MCF-7 cells (Supplementary
Figure 1B). Hypothesizing that Ser71 phosphorylation may be
a pro-survival event by inhibiting the pro-apoptotic activity of
Pfn1, we treated the stable MDA-MB-231 cells with paclitaxel,
a commonly used chemotherapy agent which was reported to
cause apoptosis in breast cancer cells more effectively upon
Pfn1 overexpression (Zaidi et al., 2016). Indeed, we detected
significantly decreased viability of Pfn1(WT)-expressing cells
compared to the control cells. While Pfn1(S71A) showed a similar
drug-sensitizing effect as Pfn1(WT), Pfn1(S71D) was completely
inactive (Figure 5A). Western blot for cleaved caspase-7
confirmed the pro-apoptotic effect of Pfn1(WT) and Pfn1(S71A)
but not Pfn1(S71D) upon paclitaxel treatment (Figure 5B).
Similar results were also observed in MDA-MB-231 stable cells
treated with doxorubicin and staurosporine (Supplementary
Figure 1C,D), two other cytotoxic agents whose apoptosis-
inducing abilities can be augmented by Pfn1 overexpression (Yao
et al., 2013; Zaidi et al., 2016).
To confirm the toggling effect of Ser71 phosphorylation
of Pfn1 on chemotherapy-induced apoptosis in vivo, we
inoculated the MDA-MB-231 stable cells expressing Pfn1(S71A)
vs. Pfn1(S71D) in the mammary fat pads of female nude
mice. Tumors formed by both cell lines grew at similar
rates as observed in the NOD/SCID mice. When the average
tumor volumes in both groups reached ∼70 mm3, mice were
randomly divided into two subgroups (n = 5 per group)
which were treated with vehicle or paclitaxel (10 mg/kg,
weekly intraperitoneal injection) for 2 weeks. Semiweekly Caliper
measurement showed an obvious tumor-regressing effect of
paclitaxel in the Pfn1(S71A) group, with the tumor volume
difference between the vehicle and paclitaxel groups being
statistically significant at the last two time points (Figure 5C).
In contrast, tumors in the Pfn1(S71D) group responded much
less to paclitaxel and no statistically significant difference in
tumor volumes between vehicle and drug groups was detected.
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FIGURE 4 | Preventing and mimicking Ser71 phosphorylation similarly abolish the antitumor activity of Pfn1. (A) Western blot analysis of exogenous wild type and
mutant Pfn1 expression in stable MDA-MB-231 cells using a pan Pfn1 antibody, controlled by actin. (B) Stable MDA-MB-231 cells from A were seeded in 96-well
plates and grown for 7 days. Relative growth rates were calculated by normalizing Alamar blue values of each subline at Day 7 to those at Day 1. Data are
mean ± SEM of four technical replicates in one experiment. P-values were based on two-tailed unpaired t-test. Same results were confirmed by more than three
independent experiments. (C) Stable MDA-MB-231 cells were injected bilaterally into the 4th mammary fat pads of 5-week-old female NOD/SCID mice (106 cells per
side, five mice per group). Caliper measurement of tumor volumes started at 4 weeks after injection. Data are the mean ± SEM of 10 tumors within each group.
P-values were based on two-tailed unpaired t-test (versus GUS control) at day 42. (D) End-point tumor weights. Data are the mean ± SEM. P-values were based on
two-tailed unpaired t-test (versus GUS control). *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. GUS and Pfn1(WT) tumor values were published in our prior
study (Diamond et al., 2015) as they were the same controls for Pfn1(S137A vs. S137D) (published) and Pfn1(S71A vs. S71D) (shown here, unpublished) in the same
mouse xenograft experiment.
Western blot using tumor lysates showed significantly higher
levels of cleaved caspase-7 in the paclitaxel-treated Pfn1(S71A)
tumors than the Pfn1(S71D) tumors (Figure 5D). Interestingly,
baseline cleaved caspase-7 levels in untreated tumors, though
much lower than in paclitaxel-treated tumors, were also higher
in the Pfn1(S71A) vs. Pfn1(S71D) tumors. Collectively, these
data suggest that Ser71 phosphorylation, by blocking actin-
binding of Pfn1, abolishes the apoptosis-sensitizing activity
of Pfn1 particularly in response to chemotherapy agents
such as paclitaxel.
Apoptotic Sensitization by Pfn1
Rrequires Actin-Binding and
Cytoplasmic Localization
The ability of Pfn1 to bind actin is crucial for its nuclear export
by exportin-6 (Stuven et al., 2003). Since Ser71 phosphorylation
disrupts actin-binding of Pfn1, we examined its effect on Pfn1
subcellular localization. Upon transfection into HEK293T cells,
YFP-tagged Pfn1(WT) and Pfn1(S71A) were predominantly
localized in the cytoplasm. However, YFP-Pfn1(S71D) was
diffusely present within cytoplasm and nucleus (Figure 2A). We
observed the same phenotype using lentivirus-infected MDA-
MB-231 cells (Figure 6A). The opposite effects of S71A vs.
S71D mutations on cell survival upon paclitaxel treatment
were observed in the context of YFP-Pfn1 similar to untagged
Pfn1 (Supplementary Figure 2B). Intrigued by the effects of
Ser71 phosphorylation on both Pfn1 subcellular localization
and chemo-sensitizing activity, we tested whether these two
phenotypes are causally linked. To do that, we forced YFP-
Pfn1 expression either in the cytoplasm or nucleus by tagging it
with a nuclear export sequence (NES, recognized by exportin-1)
or nuclear localization sequence (NLS) as previously described
(Diamond et al., 2015; Zhu et al., 2021). We virally introduced
YFP, YFP-NES-Pfn1, or YFP-NLS-Pfn1 into MDA-MB-231 cells
and determined their relative responses to paclitaxel treatment.
Compared to YFP control cells, YFP-NES-Pfn1 cells showed
higher sensitivity to paclitaxel treatment while YFP-NLS-Pfn1
cells showed less (Figure 6B). These opposite effects on
cellular survival by YFP-NES-Pfn1 and YFP-NLS-Pfn1 were also
observed in BT-549 cells, another triple-negative breast cancer
cell line (Figure 6B).
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FIGURE 5 | Ser71 phosphorylation abolishes the pro-apoptotic activity of Pfn1 in response to paclitaxel. (A) Stable MDA-MB-231 cells were seeded in 96-well plates
and treated with DMSO or paclitaxel for 7 days. Relative drug effects were calculated by normalizing Alamar blue values of drug-treated cells by DMSO-treated cells.
Data are mean ± SEM of four technical replicates in one experiment. Similar results were observed in three independent experiments. P-values were based on
two-tailed unpaired t-test (versus GUS control). (B) Stable MDA-MB-231 cells were treated with DMSO or 5 nM paclitaxel for 48 h, followed by Western blot analysis
for full-length or cleaved caspase-7 or tubulin. Cleaved caspase-7 levels were quantified by densitometry and normalized by the levels in GUS control cells in DMSO
or paclitaxel groups. (C) MDA-MB-231 stable cells expressing Pfn1(S71A) or Pfn1(S71D) were injected bilaterally into the 4th mammary fat pads of female nude mice
(10 mice per group). Tumor-bearing mice were evenly divided and treated with vehicle (0.9% sodium chloride) or paclitaxel (10 mg/kg) by intraperitoneal injection for
2 weeks. Tumor volumes were measured semiweekly by Caliper. Data are mean ± SEM. P-values were based on two-tailed unpaired t-test between vehicle and
paclitaxel treatment groups at individual time points. *p < 0.05; **p < 0.01. (D) Randomly selected tumors harvested from vehicle or paclitaxel-treated mice in (C)
were blotted for full-length or cleaved caspase-7 and GAPDH. Each tumor was from a different mouse.
Next, we examined whether the drug-sensitizing effect of
NES-Pfn1 is still under the regulation of Ser71 phosphorylation
by introducing the S71A vs. S71D mutations (Supplementary
Figure 2C). Indeed, MDA-MB-231 and BT-549 cells expressing
NES-Pfn1(S71D) showed significantly higher resistance to
paclitaxel treatment than those expressing NES-Pfn1(S71A) in
colony formation assays (Figure 6C). Western blot against
cleaved caspase-7 and cleaved PARP confirmed that paclitaxel-
induced apoptosis in NES-Pfn1(S71D)-expressing cells was
indeed significantly lower than in NES-Pfn1(S71A)-expressing
cells (Figure 6D).
The pro-apoptotic activity of Pfn1 has been causally linked
to its ability to increase p53 and IκBα (negative regulator
of NFκB) levels in breast cancer cell lines (Yao et al., 2013;
Zaidi and Manna, 2016; Zaidi et al., 2016). We found that
MDA-MB-231 stable cells expressing untagged Pfn1(S71D)
contain significantly lower levels of IκBα than those expressing
Pfn1(S71A) (Figure 6E). The difference in IκBα levels between
MDA-MB-231 cells expressing NES-Pfn1(S71A) and NES-
Pfn1(S71D) can also be seen but to a lesser extent (Figure 6E).
Interestingly, p53 levels did not differ significantly between
Pfn1(S71A) and Pfn1(S71D) cells regardless of whether Pfn1
is untagged or NES-tagged (Figure 6E). Collectively, our data
suggest that cytoplasmic Pfn1 promotes apoptosis in response to
cytotoxic treatments and such an activity is abolished by Ser71
phosphorylation via abolishing actin-binding of Pfn1 as well as
causing its nuclear retention, both of which contribute to IκBα
destabilization and increased NFκB signaling.
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FIGURE 6 | Apoptotic sensitization by Pfn1 requires actin-binding and cytoplasmic localization. (A) Direct fluorescence imaging of MDA-MB-231 stably infected with
wild type or mutant YFP-Pfn1. Scale bars represent 20 µm. (B) Stable MDA-MB-231 and BT-549 cells expressing YFP, NES-Pfn1, or NLS-Pfn1 were subjected to
colony formation assays in 24-well plates with vehicle (DMSO) or 0.5 nM paclitaxel for 7 days. Relative drug effects were calculated as the ratios between cell
numbers (based on Alamar blue values) in the paclitaxel-treated vs. vehicle conditions. (C) Stable MDA-MB-231 and BT-549 cells expressing NES-Pfn1(S71A) or
NES-Pfn1(S71D) were treated with vehicle or paclitaxel in colony formation assays and analyzed as in (B). Data are mean ± SEM of three technical replicates in one
biological experiment. Similar results were observed in three independent experiments. P-values were based on two-tailed unpaired t-test. *p < 0.05; ***p < 0.001.
(D) MDA-MB-231 and BT-549 stable cells expressing NES-Pfn1(S71A) or NES-Pfn1(S71D) were treated with DMSO or 5 nM paclitaxel for 48 h, and analyzed for
full-length or cleaved PARP and caspase-7, YFP-NES-Pfn1 (with GFP ab) and GAPDH by Western blot. (E) MDA-MB-231 stable cells expressing untagged or
NES-tagged Pfn1(S71A) vs. Pfn1(S71D) were treated with 10 nM paclitaxel for 48 h, and analyzed for IκBα, p53, and GAPDH by Western blot. (F) Hypothetical
model for the pro-apoptotic activity of cytoplasmic Pfn1 which requires actin-binding and is abolished by PKA-dependent Ser71 phosphorylation. Ser71 may also be
phosphorylated by PKA in the nucleus. Actin-free pSer71-Pfn1, due to its small size, can freely diffuse in and out of nucleus. However, nuclear pSer71-Pfn1 cannot
be actively transported into the cytoplasm by exportin-6 due to its loss of actin-binding.
DISCUSSION
Pfn1 was the first actin-binding protein identified more than
four decades ago (Carlsson et al., 1977), yet it remains uncertain
to this day whether its actin-binding ability undergoes negative
regulation by post-translational modifications. In this paper,
through candidate mutagenesis and validation using public
proteomic data and a custom-made phospho-specific antibody,
we provided evidence that the evolutionarily conserved Ser71 is
a bona fide phosphorylation site in Pfn1 selectively inhibiting
its actin-binding with little effect on its PLP-binding. This is
consistent with the fact that Ser71 is located within the actin-
binding site of Pfn1 and distal to its PLP-binding pocket (Ferron
et al., 2007). Sequence analysis combined with genetic and
pharmacological testing suggested that PKA may be one of
the kinases phosphorylating Ser71. Interestingly, it was recently
suggested that PKA can also phosphorylate Ser137 of Pfn1 (Gau
et al., 2019), a shared target site for PKC and ROCK which
specifically inhibits Pfn1 interaction with PLPs (Singh et al., 1996;
Sathish et al., 2004; Shao et al., 2008a). Nonetheless, based on co-
immunoprecipitation data using HA-Pfn1-transfected HEK293T
cells, the stoichiometry of PKA-mediated Ser71 phosphorylation
of total cellular pool of Pfn1 appeared low, as overexpression
of the alpha catalytic subunit of PKA did not cause detectable
reduction in the levels of associated actin (data not shown),
despite increasing Ser71 phosphorylation levels. This could be
due to several possible reasons. First, PKA-mediated Ser71
phosphorylation may occur to a small fraction of total cellular
Pfn1 either transiently or at specific subcellular locations. Given
the high cellular abundance of Pfn1 (>50 µM in most tissues)
(Witke, 2004), the net effect on steady-state actin-binding
would not be detectable by co-IP using whole cell lysates.
Second, PKA activity is regulated by complex mechanisms
including inhibitory binding of the regulatory subunits as well
as tethering to specific subcellular locations via the diverse
A-kinase-anchoring proteins (AKAP) (Francis and Corbin, 1994;
Harada et al., 1999). Therefore, it is possible that overexpressing
the catalytic subunit of PKA alone is insufficient to achieve
Frontiers in Cell and Developmental Biology | www.frontiersin.org 8 June 2021 | Volume 9 | Article 692269
fcell-09-692269 June 15, 2021 Time: 17:44 # 9
Wang et al. Ser71 Phosphorylation of Pfn1
optimal Pfn1 phosphorylation. In either case, more molecular
details regarding the newly identified PKA/pSer71-Pfn1 axis
and the possible involvement of other kinases remain to be
determined in the future.
Despite being an essential actin-binding protein, Pfn1
simultaneously functions as a non-classical tumor suppressor
across different malignancies including breast (Roy and Jacobson,
2004; Wittenmayer et al., 2004; Zou et al., 2007, 2009, 2010;
Bae et al., 2009, 2010; Das et al., 2009; Diamond et al., 2015),
pancreatic (Yao et al., 2014), and liver (Wu et al., 2006) cancers.
Its ability to inhibit cell cycle progression and tumor cell growth
has been demonstrated by many in vitro and in vivo studies.
Our recent work suggested that tumor growth inhibition by
Pfn1 is mediated at least in part by its nuclear function in
repressing SEC-dependent transcription of pro-cancer genes
including c-MYC (Diamond et al., 2015; Zhu et al., 2021). Such
an activity can be toggled off and on by Ser137 phosphorylation
and dephosphorylation (mimicked by S137D and S137A) which,
respectively, blocks and enables Pfn1 binding to PLPs that are
present in the SEC component ENL (Diamond et al., 2015;
Zhu et al., 2021). In this paper, by analyzing the effects of
pSer71-resistant and mimetic mutants (S71A and S71D) in MDA-
MB-231 cells, we made the unexpected observation that both
cannot inhibit tumor growth. This indicates that, rather than
functioning as an on/off switch, reversible phosphorylation and
dephosphorylation at Ser71, causing dynamic actin dissociation
and rebinding, are required for Pfn1 to inhibit tumor growth.
Given that actin-binding promotes nuclear export of Pfn1
(Stuven et al., 2003), this raises an interesting possibility
that Ser71 phosphorylation may occur in a transient and
tightly controlled manner to nuclear Pfn1 to allow its escape
from nuclear export, which is subsequently followed by Ser71
dephosphorylation to render actin-rebinding by Pfn1 for its
functional engagement in transcriptional repression. Though
speculative at the moment, this theory is consistent with
our current knowledge regarding Pfn1 functions and can be
tested in the future.
In addition to suppressing tumor growth, Pfn1 also sensitizes
cancer cells to drug-induced apoptosis. This has been best
demonstrated in breast cancer cells treated with cytotoxic agents
many of which are common cancer chemotherapies including
paclitaxel (Zou et al., 2010; Yao et al., 2013; Zaidi et al., 2016).
Although detailed molecular mechanisms underlying apoptosis-
sensitization by Pfn1 remain unknown, such an activity has
been linked to p53 and NFκB signaling. It was found that
Pfn1 and p53 co-exist in the same complex in breast cancer
cells, and Pfn1 overexpression increases total p53 protein levels
as well as its redistribution to cytoplasm and mitochondria
(Yao et al., 2013; Zaidi et al., 2016) where p53 can drive
intrinsic apoptotic pathway in a transcription-independent
fashion (Marchenko et al., 2000; Chipuk et al., 2004). In
support of the functional link between Pfn1 and p53, apoptosis-
sensitizing effect of Pfn1 was greatly reduced in p53-null and
knockdown cells (Yao et al., 2013; Zaidi et al., 2016). In addition
to enhancing p53 activity, Pfn1 was also found to decrease NFκB
signaling by preventing cytotoxin-induced IκBα phosphorylation
and degradation and consequently preventing p65 nuclear
translocation and transcription of pro-survival genes (Zaidi and
Manna, 2016; Zaidi et al., 2016). Although these studies implicate
the involvement of cytoplasmic Pfn1 in apoptotic sensitization,
direct evidence was unavailable. In this study, by tagging Pfn1
with NES or NLS, we showed that apoptotic sensitization by
Pfn1 indeed requires its cytoplasmic localization. Interestingly,
such an activity of Pfn1 can be switched off and on by pSer71-
Pfn1 mimicking and preventing mutants both in vitro and
in vivo, indicating an essential role of actin-binding. Our data
suggested that pSer71-Pfn1 could be a novel predictive biomarker
for cancer chemotherapy response. They are also consistent
with the well-known pro-survival effects of PKA, which have
been mechanistically linked to activating phosphorylation of
the cAMP-response element binding protein (CREB) in the
nucleus (Wilson et al., 1996; De Cesare and Sassone-Corsi,
2000; Mayr and Montminy, 2001; Naqvi et al., 2014) and
deactivating phosphorylation of the pro-apoptotic protein Bad in
the cytoplasm (Harada et al., 1999; Lizcano et al., 2000). Thus,
Pfn1 may be a previously unknown downstream effector of PKA
function in apoptotic inhibition through Ser71 phosphorylation.
Given that Ser71 phosphorylation prevents nuclear Pfn1 export,
we speculate that it may inhibit the apoptosis-sensitizing effect
of Pfn1 via a two-pronged mechanism by abolishing its actin-
binding and reducing its cytoplasmic levels (Figure 6F). Taken
together, our data in this paper demonstrated that Ser71 is a bona
fide phosphorylation site of Pfn1 capable of inhibiting its actin-
binding ability, preventing its nuclear export, and influencing its
tumor-inhibitory functions.
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